ESPERION THERAPEUTICS

Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

21 Feb 2023 06:00:01 By Nasdaq GlobeNewswire

Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC

20 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

13 Feb 2023 15:30:00 By Nasdaq GlobeNewswire

Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023

07 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500

11 Jan 2023 10:00:00 By Nasdaq GlobeNewswire

Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results

08 Jan 2023 18:00:00 By Nasdaq GlobeNewswire

CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)

19 Dec 2022 15:15:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

13 Dec 2022 17:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in January Investor Meetings

13 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

07 Dec 2022 07:05:00 By Nasdaq GlobeNewswire

Esperion Appoints Ben Halladay Chief Financial Officer

16 Nov 2022 15:00:00 By Nasdaq GlobeNewswire

Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus

09 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Esperion to Participate in Jefferies London Healthcare Conference

02 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update

01 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Esperion Hosting Virtual Research & Development Day

27 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

19 Oct 2022 15:00:00 By Nasdaq GlobeNewswire

Esperion to Report Third Quarter 2022 Financial Results November 1, 2022

17 Oct 2022 07:02:23 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming September Investor Conferences

30 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway

26 Aug 2022 07:16:14 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

04 Aug 2022 15:05:01 By Nasdaq GlobeNewswire